Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DNTH 
Dianthus Therapeutics Inc. (DNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: DNTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $61.96
1 Year Target Price $61.96
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 125.4% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.55B USD | Price to earnings Ratio - | 1Y Target Price 61.96 |
Price to earnings Ratio - | 1Y Target Price 61.96 | ||
Volume (30-day avg) 12 | Beta 1 | 52 Weeks Range 13.37 - 39.87 | Updated Date 09/18/2025 |
52 Weeks Range 13.37 - 39.87 | Updated Date 09/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -18096.89% |
Management Effectiveness
Return on Assets (TTM) -23.37% | Return on Equity (TTM) -34.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1290403140 | Price to Sales(TTM) 318.92 |
Enterprise Value 1290403140 | Price to Sales(TTM) 318.92 | ||
Enterprise Value to Revenue 265.84 | Enterprise Value to EBITDA -7.35 | Shares Outstanding 39816200 | Shares Floating 15786774 |
Shares Outstanding 39816200 | Shares Floating 15786774 | ||
Percent Insiders 6.36 | Percent Institutions 100.97 |
Upturn AI SWOT
Dianthus Therapeutics Inc.
Company Overview
History and Background
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics that target the classical complement pathway. Founded in 2019, the company is headquartered in Waltham, MA. It went public in July 2023.
Core Business Areas
- Complement Therapeutics: Developing novel therapeutics that target the classical complement pathway.
- Lead Program (DNTH103): Development of DNTH103, a potent, selective, and long-acting inhibitor of classical complement C1s.
Leadership and Structure
CEO: Marino Garcia; Leadership team consists of individuals with experience in drug development and biotechnology. Operates as a biotechnology company with research, development, and clinical trial functions.
Top Products and Market Share
Key Offerings
- DNTH103: DNTH103 is Dianthus' lead product, designed to inhibit C1s, a component of the classical complement pathway. It is currently in clinical trials for generalized myasthenia gravis (gMG). Market share data is not yet available as it's still in clinical trials. Competitors developing complement inhibitors include Alexion (AZN), UCB (UCB), and Novartis (NVS). These all target different complement cascade targets.
Market Dynamics
Industry Overview
The complement therapeutics market is growing, driven by increasing understanding of complement's role in autoimmune and inflammatory diseases. It is competitive with several large pharmaceutical companies.
Positioning
Dianthus is positioning itself as a leader in classical complement pathway inhibition with a focus on developing highly selective and long-acting therapeutics. Focuses on a different approach with C1s inhibition.
Total Addressable Market (TAM)
The TAM for complement inhibitors is expected to reach billions of dollars, driven by indications like gMG, lupus nephritis, and other autoimmune disorders. Dianthus aims to capture a significant share with its selective C1s inhibitor.
Upturn SWOT Analysis
Strengths
- Novel C1s inhibitor approach
- Experienced management team
- Strong preclinical and early clinical data
- Targeting a well-validated pathway
Weaknesses
- Single asset company, high reliance on DNTH103
- Early stage clinical development
- Dependent on successful clinical trial outcomes
- Limited financial resources compared to larger competitors
Opportunities
- Expansion to additional indications beyond gMG
- Potential for partnerships or acquisitions
- Growing market for complement inhibitors
- Positive clinical trial results could significantly increase stock value
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Changes in the reimbursement landscape
- Patent Challenges
Competitors and Market Share
Key Competitors
- AZN
- UCB
- NVS
Competitive Landscape
Dianthus competes with larger, more established pharmaceutical companies. Its advantage lies in its novel C1s inhibitor approach and focus on selectivity and long duration of action. This market share data represents the entire complement therapeutics market and does not isolate classical pathway inhibition; DNTH is pre-revenue.
Growth Trajectory and Initiatives
Historical Growth: N/A (Newly Public)
Future Projections: Future growth depends on the successful development and commercialization of DNTH103 and other potential pipeline assets. Analyst estimates will be available after the first few quarters of trading.
Recent Initiatives: Focus on advancing DNTH103 through clinical trials, exploring additional indications, and building a pipeline of complement inhibitors.
Summary
Dianthus Therapeutics is a promising clinical-stage biotech company with a novel approach to complement inhibition. Its future hinges on the success of its lead asset, DNTH103, and faces competition from established players. Positive clinical trial results will be crucial for its growth. As a newly public company, Dianthus needs to manage its resources effectively to navigate the clinical development process and potentially secure partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (if available)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dianthus Therapeutics Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-09-12 | President, CEO & Director Mr. Marino Garcia M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://dianthustx.com |
Full time employees 78 | Website https://dianthustx.com | ||
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.